You know Hims, right? It's the next-gen telehealth startup famous for taking the eye contact out of erectile dysfunction treatment. Of course, bedroom pills aren't all Hims peddles. The Uberized ...

I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an all-time high by late February – only to plunge by half in ...

What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand. Shares of the health and wellness platform operator ...

Hims & Hers (NYSE: HIMS) has seen incredibly high growth, but the market is skeptical that will continue. In this video, Travis Hoium shows just how cheap the stock is today. *Stock prices used ...

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company ...

Hims & Hers Health stock plummeted after an FDA decision that prevents the company from selling compounded semaglutide. The company still expects to deliver strong revenue growth, though, and ...

It has been about a month since the last earnings report for Hims & Hers Health, Inc. (HIMS). Shares have lost about 7.1% in that time frame, underperforming the S&P 500. Will the recent negative ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...